The Hedgehog (Hh) pathway is critical for cell differentiation, tissue polarity, and stem cell maintenance during embryonic development, but is silent in adult tissues under normal conditions.
Patients suffering from advanced basal cell carcinoma (BCC) have very limited treatment options. Sonidegib selectively inhibits the growth of Hedgehog pathway-dependent tumors and can treat ...
Novartis announced the FDA has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with...
Sun Pharmaceutical Industries Ltd and its subsidiaries or associate companies announced its plans to acquire a branded oncology product, Odomzo...
On 25 June 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...
The European Commission has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules, from Novartis, for the treatment of adult patients...
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent type of malignancy in Caucasians worldwide. Several factors have been correlated with aggressiveness and likelihood of recurrence...
Summary: The present study reviews the current definition of advanced cSCC and discusses the new systemic approaches, including checkpoint inhibitors.
Advanced (i.e., unresectable) cutaneous squamous cell carcinoma (cSCC) is a rare condition with a dismal prognosis. Although less than 5% of cSCC patients develop metastases or local recurrence after...